Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN22530 · 1 trial · 2 indications
Part A and B
Part C
| Arm | Type | Description |
|---|---|---|
| Phase 1 Part A | EXPERIMENTAL | - |
| Phase 1 Part B | EXPERIMENTAL | - |
| Phase 2 Part C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN22530 | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol 2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20/200) in the study eye on day 1 3. ...
REGN22530 is an investigational small molecule being developed for Primary Open Angle Glaucoma (POAG). It is also being studied in Ocular Hypertension (OHT). The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
REGN22530 is being developed by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The company is conducting a Phase 1 clinical trial to evaluate the drug in adults with Primary Open Angle Glaucoma or Ocular Hypertension.
REGN22530 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is a randomized, double-blind, controlled study that is not yet recruiting participants.
REGN22530 is being studied in one Phase 1 clinical trial, NCT07675824, titled 'REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension'. The trial has an enrollment of 271 participants and is currently not yet recruiting.
REGN22530 is the only name provided for this investigational drug. It is a small molecule being developed by Regeneron Pharmaceuticals for the treatment of Primary Open Angle Glaucoma and Ocular Hypertension.